Nucleoside analogs are transformative in cancer and antiviral therapies, offering new avenues for treatment despite ...

The "Human Immunodeficiency Virus (HIV): Epidemiology Forecast to 2033" report has been added to ResearchAndMarkets.com's offering. This report provides an overview of the risk factors, comorbidities, ...

He is also a doctor who is proud of his work to get tens of thousands of children vaccinated against hepatitis B, a disease that can lead to liver ... websites could spread far and wide since the ...

The Recombinant DNA Technology Market size is expected to be worth around USD 1288.5 Bn by 2032 from USD 786.7 Bn in 2023, growing at a CAGR of 5.8% As scientific and technological advancements ...

After a brief overview of the role of cccDNA in the HBV infectious cycle ... potentially curative therapies of chronic hepatitis B. A second key for HBV persistence is a flawed immune response, ...

An Overview of Pelvic Inflammatory Disease (PID ... Viral sexually transmitted infections include HIV, herpes, HPV, and hepatitis B.

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish ...

Precision BioSciences reports early PBGENE-HBV trial data showing safety and antiviral activity in chronic Hepatitis B patients, with more results expected in 2025.

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, research led by Memorial Sloan Kettering Cancer Center ...

Assessment of liver fibrosis and cirrhosis is crucial for the management of patients with chronic hepatitis B. The presence of at least moderate liver fibrosis is an important indication for antiviral ...

The trial was tailored to evaluate the therapy at multiple ascending dose levels, with three dose administrations per level.

Goldman Sachs downgraded Dynavax to Sell, citing increased competition in the shingles vaccine market and uncertainty over hepatitis B revaccination demand.